Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations

This publication has 24 references indexed in Scilit:

• Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
  Journal of Clinical Oncology, 2009
• A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
  Cancer Research, 2008
• Defining the Role of mTOR in Cancer
  Cancer Cell, 2007
• Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
  Clinical Cancer Research, 2006
• Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer
  Journal of Clinical Oncology, 2004
• The tor pathway: a target for cancer therapy
  Nature Reviews Cancer, 2004
• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
  Annals of Oncology, 2003
• An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten^+/−mice
  Proceedings of the National Academy of Sciences, 2001
• RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
  The Lancet, 1989